Beta-O2 ßAir bioartificial pancreas (oxygen-refueled macrocapsule)
Beta-O2 Technologies Ltd.
What it is
A macroencapsulation device that addresses encapsulation's classic weakness — oxygen starvation — by building in a refillable oxygen tank that is topped up daily. In a Phase 1 trial, implanted human islets survived for months behind the membrane with no immunosuppression, but insulin output was too low to affect blood sugar, exposing how hard it is to keep enough cells alive in a capsule.
Editorial review: .
Most recent recorded citation date: 2026-04-28. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence behind this assessment
Key evidence notes. Study results, product eligibility and access answer different questions.
- Who was studied?
- Study populations and analysis groups vary. Product age limits alone do not describe who was studied.
- Benefit or performance
- Insulin independence: Only minute levels of circulating C-peptide were seen, with no impact on metabolic control; the device came nowhere near reducing insulin needs.[1]
- Important harms and treatment burden
- Immunosuppression-free: Implantation successfully prevented immunization and rejection of allogeneic islets without any immunosuppressive therapy — the membrane provided real local immune isolation.[1]
- Approval and country access
- Country-specific approval and access are not summarized in this record.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
- Follow-up and remaining uncertainty
- Durability: Islets survived for several months behind the membrane, but fibrosis with immune cells formed around the capsule and recovered devices showed blunted insulin response and amyloid formation.[1]
Research status alone does not establish approval, clinical benefit or local availability.
Editorial score: calculation and evidence
A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.
Default calculation: 70 × 30 + 5 × 20 + 25 × 20 + 35 × 10 + 15 × 5 + 25 × 15 = 3500; divide by total weight 100. Unrounded weighted result: 35.
Implantation successfully prevented immunization and rejection of allogeneic islets without any immunosuppressive therapy — the membrane provided real local immune isolation.[1]
Only minute levels of circulating C-peptide were seen, with no impact on metabolic control; the device came nowhere near reducing insulin needs.[1]
Islets survived for several months behind the membrane, but fibrosis with immune cells formed around the capsule and recovered devices showed blunted insulin response and amyloid formation.[1]
The device is retrievable, but it is a surgical implant whose oxygen chamber must be refilled daily, adding a substantial maintenance burden.[1]
Demonstrated only in a small Phase 1 cohort of adults with long-standing type 1 diabetes; the surgical implant and daily oxygen refills would constrain broad use.[2]
A completed Phase 1 study published in a peer-reviewed journal with a follow-on pilot registered, but human islet function remained limited, falling short of what would justify advancing as a therapy.[1]
The full picture
Macroencapsulation — sealing many islets behind one semi-permeable membrane — is conceptually simple but fights a brutal problem: cells packed together quickly run out of oxygen. The Beta-O2 ßAir device tackles this head-on with an engineered solution: islets are embedded in alginate slabs behind a semi-permeable membrane, and the device carries a built-in, refillable oxygen reservoir that the patient tops up daily to keep the cells alive.
In a Phase 1 study at Uppsala, four adults with type 1 diabetes received one or two ßAir devices, each holding roughly 155,000–180,000 islet equivalents, monitored for three to six months. The encouraging finding was immune isolation: the membrane prevented immunization and rejection of the donor islets with no immunosuppressive drugs at all, and beta cells survived inside. The disappointing finding was function: only minute amounts of C-peptide reached the bloodstream, with no effect on blood-sugar control. Recovered devices showed a blunted insulin response, fibrotic tissue with immune cells around the capsule, and amyloid in the endocrine tissue.
The device is retrievable and showed the membrane could protect cells, but the results crystallize encapsulation's core tension — even with active oxygenation, keeping enough cells alive and freely secreting insulin through a barrier remains unsolved. It stands as an instructive research platform rather than a near-term therapy.
Coming soon
ETA · No live programme to wait for. The pilot (NCT02064309, Uppsala University Hospital, 4 participants) is still listed as active-not-recruiting and the registry shows a 2027 completion date, but the study started in 2014 and its results were published in 2018 — that date is stale registry housekeeping, not a readout to expect. Device function in humans never reached a level of metabolic benefit, so this is a research-stage platform.
Sources
- [1]
- [2]Transplantation of Macro-encapsulated Human Islets Within the Bioartificial Pancreas Beta-Air in Patients With Type 1 Diabetes Mellitus · Trial registry · 2026-04-28 — Sponsor Uppsala University Hospital, with Beta-O2 Technologies as collaborator; 4 participants; started February 2014; no results posted. Live-checked 27 August 2026: still listed active-not-recruiting, with a May 2027 completion date that is stale registry housekeeping rather than an expected readout.